Strong frameworks for safety, standardization, and policy development are required due to the expanding utilize of microbiota in the food, agricultural, and therapeutic sectors. This chapter provides a comprehensive analysis of the difficulties and methods currently used to assess the safety of products derived from microbiota such as toxigenicity assessment, clinical safety validation, microbial strain selection, and antibiotic resistance profiling. The fact that sampling, sequencing techniques, bioinformatics pipelines and metadata reporting are still applied differently across studies and geographical locations emphasizes the need for uniform and repeatable standards in microbiota research. A substantial research gap is the absence of widely accepted criteria for the efficacy of microbiota-based treatments with respect to strains, dosage regularity and long-term impact assessment. Furthermore, the lack of a comprehensive international regulatory consensus complicates the classification and approval processes for medications and agricultural inputs derived from microbiota. Examples of ethical, legal and social problems that highlight the necessity of inclusive and open policy development include benefit sharing, bio-prospecting and consumer misinformation. Future perspectives suggest that the development of globally standardized standards has the capacity to be aided by interdisciplinary collaborations, flexible regulatory frameworks that has the capacity to accommodate new microbiome technologies and the utilize of digital tools such as blockchain, artificial intelligence and omics-based surveillance for real time safety and quality control. The chapter concludes with a call for evidence-based policymaking and improved public private partnerships to support the responsible development, marketing and governance of microbiota-based solutions globally.